Price Rises Return Akorn To Sales Growth
Continuing To Work Through Facility Compliance Issues
Raising prices for certain product lines helped Akorn to post its first sales growth since 2016 as the US injectables and ophthalmics firm worked towards addressing two FDA warning letters.
